<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Ophthalmology</title><link>https://nrouizem.github.io/test/ophthalmology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/ophthalmology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sat, 22 Mar 2025 01:17:43 +0000</lastBuildDate><item><title>The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root</title><link>https://www.drugdiscoverytrends.com/the-fda-fast-tracked-gnsc-001-gene-therapy-targets-osteoarthritis-at-its-root/</link><description>The FDA has fast-tracked GNSC-001, a gene therapy aimed at addressing the root causes of osteoarthritis, a condition impacting over 30 million Americans and costing the healthcare system nearly $460 billion annually. This innovative treatment represents a significant advancement in the quest for effective osteoarthritis therapies.</description><pubDate>Tue, 04 Feb 2025 19:16:27 +0000</pubDate></item><item><title>JAMA: Potential rare vision complications linked to blockbuster GLP-1s</title><link>https://www.drugdiscoverytrends.com/jama-potential-rare-vision-complications-linked-to-blockbuster-glp-1s/</link><description>A new case series in JAMA Ophthalmology revealed that nine patients taking semaglutide or tirzepatide experienced sudden vision changes, raising concerns about potential rare complications from these popular diabetes and weight loss medications. This investigation underscores the need for further research on the safety of glucagon-like peptide-1 receptor agonists.</description><pubDate>Tue, 11 Feb 2025 17:14:58 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>Rosnilimab, a novel treatment for rheumatoid arthritis (RA), shows promise in a phase 2b trial by targeting the PD-1 pathway to reset the immune system, offering hope for long-term remission. This innovative approach aims to provide sustained relief for patients who often cycle through current therapies like methotrexate and biologics.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>Q&amp;A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results</title><link>https://www.drugdiscoverytrends.com/qa-anaptysbios-cmo-on-rosnilimabs-compelling-phase-2b-ra-results/</link><description>AnaptysBio has announced promising results from its Phase 2b RENOIR clinical trial for rosnilimab, with nearly 70% of participants achieving low disease activity by Week 14. The investigational treatment met its primary endpoint, showing significant improvements in DAS28-CRP scores compared to placebo.</description><pubDate>Fri, 28 Feb 2025 16:41:52 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals’ first-of-its-kind cell therapy for macular telangiectasia type 2, a rare eye disease causing progressive central vision loss, marking a major advancement for patients with no prior treatment options. The therapy, which implants cells to repair retinal damage, could transform care for the condition, though the article does not mention specific business deals or partnerships related to its development.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item><item><title>Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial</title><link>https://endpts.com/novo-nordisks-cagrisema-shows-15-7-weight-loss-in-second-pivotal-trial/</link><description>Novo Nordisk announced Monday that its drug CagriSema achieved 15.7% weight loss in patients with obesity and type 2 diabetes after over a year of use, marking a potential advancement in dual-treatment therapies. The result underscores the drug’s efficacy in addressing these interconnected conditions, positioning it as a promising contender in the competitive metabolic health market.</description><pubDate>Mon, 10 Mar 2025 12:21:18 +0000</pubDate></item><item><title>J&amp;J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu</title><link>https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu</link><description>New late-stage trial data reveals Johnson &amp; Johnson’s psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s Sotyktu in clearing skin and reducing symptom severity for patients with plaque psoriasis. The findings could intensify competition in the dermatology treatment market, positioning J&amp;J’s therapy as a potential challenger in this therapeutic area.</description><pubDate>Mon, 10 Mar 2025 14:03:00 +0000</pubDate></item><item><title>BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis</title><link>https://www.biospace.com/drug-development/bms-sotyktu-notches-phase-iii-win-in-psoriatic-arthritis</link><description>In the plaque psoriasis market, Sotyktu is locked in a competitive battle with Amgen’s Otezla while bracing for new rivalry from Alumis’ investigational TYK2 inhibitor. The intensifying competition underscores the dynamic landscape of psoriasis treatments as emerging therapies threaten to disrupt established players.</description><pubDate>Mon, 10 Mar 2025 14:07:24 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Mineralys shares climb on study data for blood pressure drug</title><link>https://www.biopharmadive.com/news/mineralys-lorundrostat-hypertension-study-results/742000/</link><description>New studies on Mineralys' hypertension treatment have validated the drug as a promising near-commercial product, with analysts hailing it as a "derisked, almost-commercial stage cardiometabolic asset." While no specific deals or partnerships were mentioned, the data bolsters the therapy’s market potential and positions it for future commercial opportunities.</description><pubDate>Mon, 10 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>J&amp;J, Protagonist outline first IBD win for potential immunological blockbuster</title><link>https://endpts.com/jj-protagonist-outline-first-ibd-win-for-potential-immunological-blockbuster/</link><description>Johnson &amp; Johnson and Protagonist Therapeutics have partnered to develop an oral IL-23 drug, aiming to create a breakthrough immunology treatment. The companies announced progress toward this goal on Monday, signaling potential advancements in bringing the blockbuster drug candidate closer to market.</description><pubDate>Mon, 10 Mar 2025 16:04:34 +0000</pubDate></item><item><title>#AAD25 roundup: Data from Amgen, Bristol Myers, J&amp;J, Alumis and more</title><link>https://endpts.com/aad25-roundup-data-from-amgen-bristol-myers-jj-alumis-and-more/</link><description>At the American Academy of Dermatology annual meeting, key players like Amgen, Bristol Myers Squibb, Alumis, and Kyowa Kirin spotlighted updates on their dermatology drug pipelines, though no mergers or acquisitions were highlighted. The event emphasized breakthroughs in treatments for conditions like psoriasis and eczema, showcasing the industry’s focus on advancing innovative therapies for skin diseases.</description><pubDate>Mon, 10 Mar 2025 16:37:26 +0000</pubDate></item><item><title>Deep Dive: Cardiovascular Disease Back in the Spotlight</title><link>https://www.biospace.com/drug-development/deep-dive-cardiovascular-disease-back-in-the-spotlight</link><description>BioSpace highlights the rapid evolution of emerging therapeutic modalities, from gene editing to cell therapies, as biotech and pharma companies race to innovate in a competitive market. The article underscores the intensifying battles for dominance in this space, with advancements poised to reshape treatment paradigms and spur significant industry growth.</description><pubDate>Mon, 10 Mar 2025 16:40:00 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>Novo’s Wegovy successor disappoints in second large trial</title><link>https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/</link><description>A recent study found that CagriSema, a weight-loss therapy for individuals with obesity and diabetes, demonstrated effectiveness in aiding weight loss but fell short of outperforming Eli Lilly’s rival drug Zepbound. While the results highlight CagriSema’s potential, they solidify Zepbound’s competitive edge in the burgeoning metabolic treatment market.</description><pubDate>Mon, 10 Mar 2025 17:17:00 +0000</pubDate></item><item><title>Beam base editing therapy gets ‘proof of concept’ in rare lung disease</title><link>https://www.biopharmadive.com/news/beam-aatd-base-editing-initial-data-results-302/742015/</link><description>Beam Therapeutics' shares dropped sharply despite promising early study results showing its gene-editing technology could address the genetic cause of alpha-1 antitrypsin deficiency. The stock decline highlights investor concerns even as the company advances its innovative treatment potential.</description><pubDate>Mon, 10 Mar 2025 17:25:00 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, or steroids, remain the standard treatment for various autoimmune disorders due to their effectiveness in suppressing inflammation and alleviating symptoms. However, the article highlights the hidden costs and potential long-term toxicity associated with steroid use, raising concerns about their overall impact on patient health.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD</title><link>https://www.biospace.com/drug-development/beams-gene-editor-achieves-first-ever-genetic-correction-in-aatd</link><description>William Blair analysts highlighted BEAM-302 as a breakthrough therapy, praising its superior efficacy in its sector in a recent investor note. While the report emphasized the drug's potential to redefine treatment standards, it did not mention any specific business deals, partnerships, or acquisitions related to the product.</description><pubDate>Tue, 11 Mar 2025 13:52:59 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Viking inks CordenPharma deal to boost obesity drug supply</title><link>https://www.biopharmadive.com/news/viking-cordenpharma-obesity-drug-manufacturing-deal/742139/</link><description>A biotech firm is investing $150 million in a strategic alliance to secure expanded production capacity for a high-profile weight-loss therapy, positioning itself to meet soaring demand. The partnership underscores the company’s aggressive push to capitalize on the competitive but rapidly growing market for obesity treatments.</description><pubDate>Tue, 11 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Agenus CMO touts immunotherapy advances on The Top Line</title><link>https://www.fiercebiotech.com/sponsored/agenus-cmo-touts-immunotherapy-advances-top-line</link><description>Agenus Chief Medical Officer highlighted significant advancements in immunotherapy during a recent discussion on The Top Line, emphasizing the company's commitment to innovative cancer treatments. The conversation underscored Agenus's strategic focus on enhancing patient outcomes through its developing therapies and ongoing research.</description><pubDate>Tue, 11 Mar 2025 17:26:30 +0000</pubDate></item><item><title>How technology advances are helping scientists unlock the mysteries of zoonotic diseases</title><link>https://www.drugdiscoverytrends.com/how-technology-advances-are-helping-scientists-unlock-the-mysteries-of-zoonotic-diseases/</link><description>In 2024, the World Health Organization expanded its pandemic watchlist by adding 24 pathogens, including three zoonotic diseases: avian influenza, mpox (formerly monkeypox), and the Sin Nombre virus, which has a 30% fatality rate. The article explores how technological advancements are aiding scientists in understanding these complex zoonotic diseases.</description><pubDate>Tue, 11 Mar 2025 17:27:25 +0000</pubDate></item><item><title>How biosimulation and virtual trials can bust through clinical trial roadblocks</title><link>https://www.drugdiscoverytrends.com/how-biosimulation-and-virtual-trials-can-bust-through-clinical-trial-roadblocks/</link><description>Over 300 million people globally suffer from rare diseases, with 95% lacking FDA-approved treatments due to the challenges of traditional clinical trials. However, biosimulation and virtual trial methods are emerging as promising solutions to overcome these barriers, as highlighted by expert Oxana Iliach.</description><pubDate>Fri, 14 Mar 2025 15:54:00 +0000</pubDate></item><item><title>Altimmune Jumps On Takeover Rumors After Launching Alcohol Use Disorder Study</title><link>https://www.biospace.com/business/altimmune-jumps-on-takeover-rumors-after-launching-alcohol-use-disorder-study</link><description>The company announced its plans to initiate testing of a dual receptor agonist targeting GLP-1 and glucagon for the treatment of alcohol use disorder and alcohol-related liver disease. This innovative approach aims to address significant health challenges associated with excessive alcohol consumption.</description><pubDate>Mon, 17 Mar 2025 12:44:24 +0000</pubDate></item><item><title>How Proscia is using AI embeddings to transform drug discovery in pathology</title><link>https://www.drugdiscoverytrends.com/how-proscia-is-using-ai-embeddings-to-transform-drug-discovery-in-pathology/</link><description>Proscia is leveraging AI-powered pathology analysis to revive a lung cancer drug candidate by developing an algorithm that identifies which patients are likely to benefit from the treatment. This innovative use of machine learning and digital pathology could significantly impact drug discovery processes in the pharmaceutical industry.</description><pubDate>Mon, 17 Mar 2025 20:43:21 +0000</pubDate></item><item><title>Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies</title><link>https://www.biospace.com/drug-development/sarepta-shares-crash-22-after-patient-on-dmd-gene-therapy-elevidys-dies</link><description>Sarepta Therapeutics is updating the label for its Duchenne muscular dystrophy gene therapy, Elevydis, following a patient's death attributed to liver injury. The decision aims to enhance safety awareness surrounding the treatment.</description><pubDate>Tue, 18 Mar 2025 14:00:23 +0000</pubDate></item><item><title>GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors</title><link>https://www.biospace.com/business/glp-1-drug-boom-recalls-the-rise-of-pd-1-checkpoint-inhibitors</link><description>The rise of GLP-1 weight loss drugs parallels the initial success of PD-1 inhibitors, yet significant market differences indicate that the outcomes may differ this time around. As the industry evolves, these nuances could shape the future landscape of obesity treatment and pharmaceutical investments.</description><pubDate>Wed, 19 Mar 2025 06:11:00 +0000</pubDate></item><item><title>Optum Rx says it will eliminate some prior authorization requirements</title><link>https://www.biopharmadive.com/news/optum-rx-eliminate-prior-authorizations/742964/</link><description>The PBM announced it will eliminate the requirement for coverage reauthorization on around 80 drugs, including Vertex's cystic fibrosis treatments and several medications for multiple sclerosis. This change aims to improve patient access and streamline the prescription process for these critical therapies.</description><pubDate>Wed, 19 Mar 2025 16:07:00 +0000</pubDate></item><item><title>Novartis’ Intrathecal Zolgensma Effective in Older Children</title><link>https://www.biospace.com/drug-development/Novartis-intrathecal-zolgensma-effective-in-older-children</link><description>Novartis is launching an intrathecal formulation of Zolgensma, targeting older patients affected by spinal muscular atrophy, following its initial market debut in 2019 as the first gene therapy for the condition. This new formulation aims to expand treatment options and improve patient outcomes in a previously underserved population.</description><pubDate>Wed, 19 Mar 2025 20:32:50 +0000</pubDate></item><item><title>In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On</title><link>https://www.biospace.com/drug-development/in-wake-of-elevydis-death-duchenne-patient-community-vows-to-push-on</link><description>Sarepta faced scrutiny following the death of a patient who had received its gene therapy Elevidys, prompting a strong response from the advocacy group Parent Project Muscular Dystrophy. The group's involvement highlights ongoing concerns regarding the safety and efficacy of experimental treatments in the field of muscular dystrophy.</description><pubDate>Thu, 20 Mar 2025 13:25:20 +0000</pubDate></item><item><title>Servier and Black Diamond sign deal for solid tumours therapy</title><link>https://www.pharmaceutical-technology.com/news/servier-black-diamond-deal/</link><description>Servier has entered into a licensing agreement with Black Diamond Therapeutics for BDTX-4933, a targeted therapy designed to combat solid tumors. This partnership highlights both companies' commitment to advancing innovative cancer treatments.</description><pubDate>Thu, 20 Mar 2025 13:42:55 +0000</pubDate></item><item><title>Novartis builds case for new SMA gene therapy</title><link>https://www.biopharmadive.com/news/novartis-oav101-sma-gene-therapy-results-filing/743087/</link><description>Novartis reported promising late-stage data suggesting that its intrathecal drug, sharing the active ingredient of the gene therapy Zolgensma, may gain approval for a wider array of spinal muscular atrophy patients. This development could significantly enhance treatment options for those affected by the condition.</description><pubDate>Thu, 20 Mar 2025 16:26:00 +0000</pubDate></item><item><title>SV Health Investors nabs $250M to fund dementia-focused biotechs</title><link>https://endpts.com/sv-health-investors-nabs-250m-to-fund-dementia-focused-biotechs/</link><description>SV Health Investors has successfully raised $250 million for its Dementia Discovery Fund 2, aimed at advancing new therapeutics for dementia, Alzheimer's, and other neurodegenerative diseases. This significant funding boost underscores the investor's commitment to addressing critical challenges in neuroscience and improving patient outcomes.</description><pubDate>Thu, 20 Mar 2025 17:15:35 +0000</pubDate></item><item><title>Many rare disease drugs rely on just one trial for approval, FDA authors find</title><link>https://endpts.com/many-rare-disease-drugs-rely-on-just-one-trial-for-approval-fda-authors-find/</link><description>Recent FDA research reveals that 67% of marketing applications for non-oncologic rare diseases approved from 2020 to 2023 were backed by just one clinical trial alongside confirmatory evidence for efficacy. This highlights a significant regulatory approach in the approval process for rare disease treatments, emphasizing the reliance on streamlined evidence.</description><pubDate>Thu, 20 Mar 2025 19:38:52 +0000</pubDate></item><item><title>Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy</title><link>https://www.biospace.com/drug-development/alynlams-amvuttra-approved-as-first-rnai-silencer-for-rare-type-of-cardiomyopathy</link><description>The FDA has approved Alnylam's Amvuttra, intensifying competition in the treatment of transthyretin amyloid cardiomyopathy with Pfizer and BridgeBio, who both offer transthyretin stabilizers. This approval positions Alnylam to vie directly against these established players in the burgeoning market for heart disease therapies.</description><pubDate>Thu, 20 Mar 2025 21:59:00 +0000</pubDate></item><item><title>Inside NVIDIA and ConcertAI’s alliance to build AI agents for oncology trials</title><link>https://www.drugdiscoverytrends.com/nvidia-and-concertai-team-up-to-build-ai-agents-that-collaborate-on-oncology-trials/</link><description>ConcertAI is partnering with NVIDIA to enhance oncology trials by integrating clinical-grade, multi-modal data with advanced AI "agents." This collaboration aims to advance the use of AI in healthcare, particularly in the field of cancer treatment.</description><pubDate>Fri, 21 Mar 2025 03:35:48 +0000</pubDate></item><item><title>Menarini to enhance BPDCN detection with VisualDx’s link</title><link>https://www.pharmaceutical-technology.com/news/menarini-bpdcn-visualdx/</link><description>Menarini Group has entered into a partnership with VisualDx to improve the diagnosis of patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). This collaboration aims to leverage advanced visual diagnostics to enhance patient outcomes in this rare cancer.</description><pubDate>Fri, 21 Mar 2025 10:16:05 +0000</pubDate></item><item><title>Alnylam joins three-way contest in ATTR cardiomyopathy</title><link>https://pharmaphorum.com/news/alnylam-joins-three-way-contest-attr-cardiomyopathy</link><description>Alnylam has received FDA approval for its drug Amvuttra to treat ATTR cardiomyopathy, positioning it to compete directly with therapies from Pfizer and BridgeBio. This approval marks a significant advancement for Alnylam in the growing market for cardiac treatments.</description><pubDate>Fri, 21 Mar 2025 10:17:35 +0000</pubDate></item><item><title>J&amp;J adds to IL-23 options in Crohn's after FDA approval</title><link>https://pharmaphorum.com/news/jj-adds-il-23-options-crohns-after-fda-approval</link><description>Johnson &amp; Johnson's Tremfya has received FDA approval for treating Crohn's disease, a move the company anticipates will drive a new phase of sales growth. This approval signifies an important milestone for J&amp;J as it seeks to expand its portfolio in gastrointestinal treatments.</description><pubDate>Fri, 21 Mar 2025 11:12:53 +0000</pubDate></item><item><title>Fabhalta is first FDA-approved therapy for rare disease C3G</title><link>https://pharmaphorum.com/news/fabhalta-first-fda-approved-therapy-rare-disease-c3g</link><description>Novartis' oral complement inhibitor Fabhalta has received approval as the first treatment for the rare kidney disease C3G, marking a significant advancement in addressing this condition. The company aims to achieve a $3 billion sales target, highlighting the drug's commercial potential.</description><pubDate>Fri, 21 Mar 2025 12:21:34 +0000</pubDate></item><item><title>J&amp;J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market</title><link>https://www.biospace.com/drug-development/j-j-wins-crohns-expansion-for-tremfya-as-stelara-biosimilars-enter-us-market</link><description>Johnson &amp; Johnson's label expansion for Tremfya aims to position it as a successor to Stelara, which is encountering increasing competition from biosimilars. This strategic move highlights J&amp;J's efforts to maintain its market leadership in immunology treatments.</description><pubDate>Fri, 21 Mar 2025 12:46:22 +0000</pubDate></item><item><title>China conditionally approves Hutchmed’s Tazverik for follicular lymphoma</title><link>https://www.pharmaceutical-technology.com/news/china-hutchmed-tazverik-fl/</link><description>Hutchmed's Tazverik has received conditional approval from the NMPA for the treatment of adults with relapsed or refractory follicular lymphoma. This milestone marks a significant advancement in cancer therapy options for patients in this demographic.</description><pubDate>Fri, 21 Mar 2025 14:07:11 +0000</pubDate></item><item><title>FDA approves Novartis’ Fabhalta in C3 glomerulopathy</title><link>https://endpts.com/fda-approves-novartis-fabhalta-in-c3-glomerulopathy/</link><description>Novartis’ Fabhalta has received FDA approval for the treatment of C3 glomerulopathy, an ultra-rare kidney disease in adults, marking it as the first drug specifically approved for this condition. This milestone reinforces Novartis' commitment to addressing rare diseases with targeted therapies.</description><pubDate>Fri, 21 Mar 2025 15:38:57 +0000</pubDate></item><item><title>The buildup to Chimerix's $935M cash exit to Jazz</title><link>https://endpts.com/the-buildup-to-chimerixs-935m-cash-exit-to-jazz/</link><description>Chimerix has garnered significant interest in its experimental brain tumor treatment, leading to a $935 million cash acquisition by Jazz Pharmaceuticals earlier this month. The deal underscores the growing value of innovative therapies in the oncology space, as Chimerix's treatment continues to show promise.</description><pubDate>Fri, 21 Mar 2025 16:28:15 +0000</pubDate></item><item><title>Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease</title><link>https://www.drugdiscoverytrends.com/discontinued-alzheimers-drug-shows-surprising-long-term-promise-in-genetic-form-of-the-disease/</link><description>A recent study from Washington University School of Medicine has revealed that Gantenerumab, an experimental monoclonal antibody discontinued by Roche/Genentech in 2022, can significantly delay symptoms in patients with a rare genetic form of Alzheimer's disease when administered long-term. Patients who received the drug for an average of eight years showed promising results, raising questions about the drug’s potential in future treatments.</description><pubDate>Fri, 21 Mar 2025 19:10:01 +0000</pubDate></item><item><title>Liver cancer drug combo gets its second FDA rejection</title><link>https://endpts.com/liver-cancer-drug-combo-gets-its-second-fda-rejection/</link><description>The FDA has rejected the drug combination of rivoceranib and camrelizumab, developed by Korean biotech HLB and China's Jiangsu Hengrui Pharmaceuticals, intended for treating the most common form of liver cancer. This marks another setback for the companies in their pursuit of approval for this treatment.</description><pubDate>Fri, 21 Mar 2025 22:28:58 +0000</pubDate></item></channel></rss>